A Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 2 Study to Evaluate Impact of Sunobinop (V117957) on Alcohol Craving in Subjects Diagnosed With Moderate to Severe Alcohol Use Disorder and Seeking Treatment
Latest Information Update: 20 Feb 2025
Price :
$35 *
At a glance
- Drugs Sunobinop (Primary)
- Indications Alcoholism
- Focus Therapeutic Use
- Sponsors Imbrium Therapeutics
- 13 Feb 2025 Status changed from planning to recruiting.
- 13 Jan 2025 Planned initiation date changed from 1 Sep 2024 to 1 Feb 2025.
- 09 Aug 2024 New trial record